Comparison of Apixaban Versus Enoxaparin for Venous Thromboembolism Prevention After Radical Cystectomy: The CARE Trial

Katharine F Michel; Michelle Slinger; Hanna Stambakio; Ruchika Talwar; Amy N Luckenbough; Max Kates; Sunil H Patel; Luke J Keele; Trinity J Bivalacqua

doi:10.1016/j.euf.2024.10.002

Comparison of Apixaban Versus Enoxaparin for Venous Thromboembolism Prevention After Radical Cystectomy: The CARE Trial

Eur Urol Focus. 2024 Oct 22:S2405-4569(24)00189-5. doi: 10.1016/j.euf.2024.10.002. Online ahead of print.

Authors

Katharine F Michel¹, Michelle Slinger², Hanna Stambakio³, Ruchika Talwar⁴, Amy N Luckenbough⁴, Max Kates⁵, Sunil H Patel⁵, Luke J Keele³, Trinity J Bivalacqua³

Affiliations

¹ Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: [email protected].
² Drexel University College of Medicine, Philadelphia, PA, USA.
³ Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁴ Vanderbilt University Medical Center, Nashville, TN, USA.
⁵ Brady Urological Institute, Johns Hopkins Hospital, Baltimore, MD, USA.

PMID: 39443196
DOI: 10.1016/j.euf.2024.10.002

Abstract

CARE is a pragmatic randomized clinical trial designed to compare adherence, satisfaction, patient out-of-pocket costs, and venous thromboembolism (VTE) rates between apixaban and enoxaparin prescribed as VTE prophylaxis on discharge after radical cystectomy.